A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy.

Goodnough, L T; Price, T H; Friedman, K D; Johnston, M; Ciavarella, D; Khan, N; Sacher, R; Vogler, W R; Wissel, M; Abels, R I

Goodnough, L T; Price, T H; Friedman, K D; Johnston, M; Ciavarella, D; Khan, N; Sacher, R; Vogler, W R; Wissel, M; Abels, R I.

Affiliation

Goodnough LT; Department of Medicine, Washington University, St. Louis, Missouri.

Transfusion ; 34(1): 66-71, 1994 Jan.

Article in En | MEDLINE | ID: mdl-8273133

Subject(s)

Anemia/surgery; Blood Transfusion, Autologous; Erythropoietin/therapeutic use; Adolescent; Adult; Antibodies/blood; Blood Transfusion, Autologous/adverse effects; Child; Dose-Response Relationship, Drug; Double-Blind Method; Erythropoietin/administration & dosage; Erythropoietin/toxicity; Female; Humans; Male; Middle Aged; Recombinant Proteins/immunology; Recombinant Proteins/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Blood Transfusion, Autologous / Erythropoietin / Anemia Type of study: Clinical_trials / Guideline Limits: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Language: En Journal: Transfusion Year: 1994 Document type: Article Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links